| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Astria Therapeutics, Inc. (ATXS) has 8 insiders with recent SEC Form 4 filings, including 3 buys and 0 sells. ATXS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 26.6K | - | - | |
| Dir | 26.6K | - | - | |
| Dir | 26.6K | - | - | |
| Dir | 26.6K | - | - | |
| Dir | 26.6K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2015 | Medimmune Ventures, Inc. | 10% Owner | Buy | 223,439 | $12.00 | $2,681,268.00 | +15.9% | |
| Jun 30, 2015 | Galakatos Nicholas | Director, 10% Owner | Buy | 376,695 | $12.00 | $4,520,340.00 | +15.9% | |
| Jun 30, 2015 | Laufer Ron | Director, 10% Owner | Buy | 223,439 | $12.00 | $2,681,268.00 | +15.9% |